Phase 1a/1b Study of BG-C9074, an Antibody Drug Conjugate Targeting B7H4, as Monotherapy and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
This is a first-in-human study to learn about the study drug called BG-C9074 alone and in combination with tislelizumab in participants with advanced solid tumors.
Why this Research Matters
The study drug called BG-C9075 will be given alone and in combination with tislelizumab in participants with advanced solid tumors.
Who can Participate
Adult
Detailed eligibility criteria is available on ClinicalTrials.gov. These requirements will be discussed with your doctor and/or study representative. Visit ClinicalTrials.gov to learn more about this study.
Study ID
Protocol Number: 24-1128
More information available at ClinicalTrials.gov: NCT06233942
Meet the Team
Principal Investigator
Categories
Locations
-
University of Colorado Hospital
- CTRC Inpatient